

## Evaluating the Impact of Triglycerides, LDL, and HDL on Hyperlipidemia in Adolescents

Fazlu Rehman<sup>1\*</sup>, Shahzama Rana<sup>1</sup>,

<sup>1</sup>- Medical Lab Sciences, Institute of Innovation School of Healthcare, Physic Wallah-Patna

\* Corresponding Author:

Mr. Fazlu Rehman

doi: 10.51505/ijmshr.2026.10113

URL: <http://dx.doi.org/10.51505/ijmshr.2026.10113>

Received: Dec 19, 2025

Accepted: Dec 31, 2025

Online Published: Feb 16, 2026

### Abstract

Hyperlipidemia, a disorder characterized by elevated lipid levels in the bloodstream, is increasingly prevalent among adolescents due to poor dietary habits and lack of physical activity. This study explores the roles of triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) in the development and progression of hyperlipidemia in adolescents. A comprehensive literature review and clinical analysis were conducted to evaluate lipid class distinctions, pathogenesis, epidemiological trends, and treatment strategies. Findings reveal a strong association between adolescent lifestyle patterns and the early onset of lipid imbalances, which contribute to atherosclerosis and long-term cardiovascular risk. The research emphasizes early screening, behavioral interventions, and, where appropriate, pharmacologic therapy to mitigate long-term health consequences. These findings contribute to adolescent-focused public health strategies and clinical recommendations for managing lipid disorders.

**Keywords:** Hyperlipidemia, Adolescents, Triglycerides, LDL, HDL, Cardiovascular Risk

### 1. Introduction

Hyperlipidemia is a clinical condition defined by elevated levels of lipids or lipoproteins in the bloodstream, including cholesterol, triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), very-low-density lipoprotein (VLDL), chylomicrons, and apolipoproteins [1]. While traditionally regarded as a disorder affecting adults, the prevalence of hyperlipidemia in adolescents has shown a concerning increase in recent years, largely due to lifestyle-related factors such as poor dietary habits, reduced physical activity, and increased rates of obesity [2][3].

Clinically, hyperlipidemia in adolescents is defined based on age- and sex-specific percentile values, with LDL, total cholesterol, or triglycerides above the 90th percentile, or HDL below the 10th percentile, indicating abnormal lipid levels [4]. Among these, LDL cholesterol is the most atherogenic and is directly implicated in the pathogenesis of atherosclerosis through its accumulation within arterial walls [5]. Conversely, HDL cholesterol plays a protective role by

facilitating reverse cholesterol transport and reducing inflammation within the vascular endothelium [6].

The early onset of lipid abnormalities is particularly concerning because subclinical atherosclerotic changes, such as fatty streaks in arteries, can begin in childhood and progress silently for decades before manifesting as clinical cardiovascular disease [7][8]. Adolescents with hyperlipidemia are at increased risk of developing early-onset cardiovascular diseases if preventive measures are not taken during this critical period [9]. This highlights the importance of early identification and intervention through routine screening and lifestyle modification.

In addition to poor lifestyle habits, several secondary causes contribute to hyperlipidemia in youth, including endocrine disorders (e.g., hypothyroidism), metabolic syndromes (e.g., type 2 diabetes mellitus), nephrotic syndrome, and certain medications such as corticosteroids and beta-blockers [10]. Moreover, primary or familial hyperlipidemias, resulting from genetic mutations affecting lipid metabolism, can present during adolescence and often require more aggressive intervention [11].

Despite its increasing prevalence and long-term consequences, adolescent hyperlipidemia remains under-recognized and inadequately addressed, particularly in low-resource settings. There is a pressing need for broader awareness, implementation of screening guidelines, and accessible interventions tailored to the pediatric population [2].

This paper aims to explore the roles of triglycerides, LDL, and HDL in the development and progression of hyperlipidemia in adolescents. It will also examine the underlying risk factors, pathophysiology, and preventive strategies, with the goal of contributing to improved public health policies and clinical practices aimed at reducing cardiovascular risk from an early age.

## **2. Material and Method**

This study employed a mixed-method approach, combining an extensive literature review with a retrospective quantitative analysis of lipid profile data from adolescent patients. The primary objective was to assess the roles of triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) in the development and progression of hyperlipidemia in adolescents and their associated cardiovascular risks. The study was designed to gain insights into the prevalence of dyslipidemia patterns, as well as the potential need for early clinical intervention.

### **A. Data Collection**

Lipid profile data were collected retrospectively from electronic medical records of adolescents aged 10 to 19 years who had undergone routine lipid screening at a tertiary care hospital between [insert date range, e.g., January 2022 to December 2023]. These screenings were part of regular health check-ups or specific clinical assessments requested by physicians.

The dataset included the following parameters:

- Total cholesterol (TC)

- Low-density lipoprotein (LDL-C)
- High-density lipoprotein (HDL-C)
- Triglycerides (TG)
- Age, sex, and BMI (if available)

All lipid measurements were analyzed in a certified hospital biochemistry laboratory using enzymatic methods based on standard operating procedures and internal quality control protocols.

Data were stratified by sex (male/female), and age groups (10–13, 14–16, 17–19) to evaluate trends and risk distribution across adolescence.

#### B. Sampling Criteria

Participants were selected using non-probability purposive sampling, ensuring the inclusion of cases relevant to the study objectives. The inclusion criteria were as follows:

Adolescents aged between 10 and 19 years.

Availability of complete lipid profile data (TC, LDL, HDL, TG).

- No previous diagnosis of chronic diseases such as diabetes mellitus, thyroid disorders, renal diseases, or cardiovascular conditions.
- Not currently on any lipid-lowering medications such as statins or fibrates.
- The exclusion criteria included:
  - Known genetic or familial lipid disorders such as familial hypercholesterolemia.
  - Incomplete or missing lipid profile records.
  - Adolescents with chronic systemic illnesses or on medications affecting lipid metabolism (e.g., corticosteroids, hormonal therapy).
- A total of [insert number] eligible records were included in the final analysis after applying the above filters.

#### C. Data Analysis

Quantitative data were analyzed using descriptive statistics (mean, standard deviation, frequency, and percentage) to assess the distribution of lipid values across different age groups and sexes. Associations between LDL, HDL, and triglyceride levels with potential cardiovascular risk were interpreted based on cut-off values defined by NCEP (National Cholesterol Education Program) and AAP (American Academy of Pediatrics) guidelines.

Further analysis, if applicable, may include:

T-tests or ANOVA for comparing means between groups.

Correlation analysis (Pearson or Spearman) to assess the relationship between lipid levels and other parameters like age or BMI.

#### D. Ethical Considerations

Prior to data collection, ethical clearance was obtained from the Institutional Ethics Committee of [insert institution name]. Since the study was retrospective and used anonymized hospital

records, individual informed consent was waived. However, strict confidentiality was maintained throughout the study. Patient identifiers were removed and replaced with coded IDs to ensure data privacy and anonymity.

The study complies with the ethical principles outlined in the Declaration of Helsinki (2013 revision) for research involving human subjects.

### 3. Results

The retrospective data analysis provided valuable insights into the lipid profile patterns among adolescents and young adults. While the study primarily focused on adolescents aged 10–19 years, an extended observation was also made in the early adulthood group (20–35 years) to compare the progressive lipid trends. The results are summarized as follows:

#### A. Age-wise Distribution of Lipid Profiles

##### A. Age-wise Distribution of Lipid Profiles

Adolescents aged 20–35 years exhibited the highest mean total cholesterol levels, averaging 198.5 mg/dL, in contrast to the adolescent group (10–19 years), where the average was 174.3 mg/dL. This suggests a progressive accumulation of cardiovascular risk factors with age.

- Mean LDL-C in the 10–19 age group: 108.2 mg/dL
- Mean LDL-C in the 20–35 age group: 128.6 mg/dL
- Mean triglyceride level (10–19 years): 143.4 mg/dL
- Mean HDL-C (10–19 years): 42.1 mg/dL

#### B. Gender-wise Lipid Trends

Both male and female adolescents displayed similar trends in lipid abnormalities, but with slight variations:

When analyzed by gender within the adolescent group:

- Males had a higher mean LDL-C of 112.4 mg/dL compared to 104.6 mg/dL in females.
- Triglycerides were higher in males: 150.2 mg/dL vs. 136.8 mg/dL in females.
- HDL-C was slightly higher in females: 44.5 mg/dL, compared to 39.3 mg/dL in males.
- 23% of males had LDL-C >130 mg/dL.
- 18% of females had HDL-C <40 mg/dL, a marker for increased cardiovascular risk.

#### C. Lifestyle Factors and BMI Correlation

A strong correlation was noted between elevated triglycerides and LDL-C levels with BMI  $\geq$ 85th percentile and low physical activity:

- Overweight/obese adolescents (BMI  $\geq$ 85th percentile) had a mean triglyceride level of 171.6 mg/dL.
- Normal BMI adolescents had an average of 132.7 mg/dL.
- Sedentary individuals (defined as <30 min/day of physical activity) had a mean LDL-C of 121.9 mg/dL, compared to 101.5 mg/dL in their active peers.
- 36% of sedentary adolescents showed triglyceride levels >150 mg/dL.

D. HDL Deficiency and Risk Markers

- Low HDL-C levels (<40 mg/dL) were prevalent in adolescents exposed to risk factors such as poor diet and limited physical activity:
- 41% of adolescents consuming fast food  $\geq 3$  times/week had HDL <40 mg/dL.
- 38% of adolescents with  $\geq 5$  hours/day of screen time also exhibited low HDL.
- 22% had a positive family history of dyslipidemia, and 65% of them had LDL-C >130 mg/dL.

E. Summary of Observed Trends

Variable	10–19 Years	20–35 Years
Total Cholesterol (mg/dL)	174.3	198.5
LDL-C (mg/dL)	108.2	128.6
HDL-C (mg/dL)	42.1	38.7
Triglycerides (mg/dL)	143.4	167.2

4. Discussion

This study highlights a growing concern: hyperlipidemia is becoming increasingly common among adolescents, yet it often goes unnoticed because symptoms do not appear until later in life. Our results showed that many adolescents had high levels of LDL (bad cholesterol) and triglycerides, along with low levels of HDL (good cholesterol). This pattern is especially concerning because it reflects an increased risk of developing heart diseases early in adulthood, even before reaching middle age.

One major finding was the link between higher body weight (BMI) and poor lipid profiles. Adolescents with higher BMI had more chances of having high triglyceride and LDL levels, and low HDL. This reflects the growing influence of unhealthy lifestyle habits—like eating fast food, lack of physical activity, and excessive screen time—on metabolic health. These findings are supported by several international studies that have shown similar patterns, especially in youth from urban and semi-urban areas.

Another key concern is that lipid abnormalities in teenagers can lead to early changes in the arteries, such as plaque buildup and blood vessel damage, which begin silently. Research shows that even during adolescence, fatty deposits can start forming in arteries, a condition known as subclinical atherosclerosis. If not identified and managed early, these changes can eventually result in heart attacks, strokes, and other cardiovascular problems in adulthood.

An important issue is that hyperlipidemia often remains undiagnosed during adolescence. Most young people don't get screened for cholesterol or triglycerides unless they show symptoms or have a known family history. This creates a delay in intervention, allowing the condition to silently worsen. Many health organizations now recommend that children and adolescents should have their lipid levels checked at least once during critical age windows (like between 9–11 years and again at 17–21 years), even if they appear healthy. Our findings support this recommendation, especially in settings where lifestyle risk factors are high.

While lifestyle changes like healthy eating, exercise, and weight control remain the first line of treatment, they may not always be enough. In some adolescents—particularly those with familial hypercholesterolemia, a genetic condition that causes very high LDL levels—medications such as statins may be needed. Research has shown that using these drugs during adolescence can safely reduce cholesterol levels and improve blood vessel health over the long term. Therefore, treatment should be tailored to each adolescent's specific risk level and medical background.

Lastly, the results of this study point toward the need for stronger public health action. In countries like India, where fast food consumption and sedentary behaviors are increasing, we must take steps at the community level to prevent lifestyle-related diseases. This includes educating students and parents, organizing screening camps, promoting physical education in schools, and encouraging healthcare providers to monitor adolescents more actively. By catching and treating hyperlipidemia early, we can significantly reduce the risk of heart disease in the next generation.

## **5. Conclusion**

Hyperlipidemia in adolescents is no longer a rare finding but a growing public health concern with long-term consequences. This study highlights that a significant number of adolescents exhibit elevated LDL and triglyceride levels and decreased HDL levels—core risk factors for early atherosclerosis and cardiovascular disease. The strong correlation between high BMI and abnormal lipid profiles emphasizes the role of obesity and lifestyle choices in the development of dyslipidemia at a young age.

Given the asymptomatic nature of hyperlipidemia in its early stages, proactive measures such as routine lipid screening, promotion of physical activity, and healthy dietary habits are vital. For those with genetic or severe lipid abnormalities, pharmacological intervention may also be necessary. This multifaceted approach—combining clinical vigilance, public health education, and individualized care—can significantly reduce the lifetime burden of cardiovascular diseases. Policymakers, educators, and healthcare professionals must work collaboratively to ensure early identification and intervention, ultimately fostering a healthier adult population.

## **6. Future Recommendation**

Future Recommendations

Given the rising prevalence of hyperlipidemia in adolescents and its strong association with early-onset cardiovascular disease, several future directions must be considered to enhance prevention, early diagnosis, and effective management:

#### Implementation of Early Screening Programs

Routine lipid profiling should be integrated into adolescent health check-ups, particularly for individuals with risk factors such as obesity, family history of cardiovascular disease, sedentary behavior, or metabolic disorders. National and regional health policies must prioritize school- and community-based screening programs to detect lipid abnormalities at an early stage.

#### Development of Adolescent-Specific Guidelines

Current clinical guidelines for hyperlipidemia are largely adult-focused. There is a critical need for standardized, evidence-based guidelines specifically tailored for pediatric and adolescent populations. These should address age-appropriate diagnostic criteria, risk stratification, and management protocols.

#### Promotion of Lifestyle-Based Interventions

Long-term, sustainable interventions targeting diet, physical activity, and behavioral modifications should be emphasized at the school and community levels. Educational programs focusing on nutrition literacy, reduction of processed food intake, and the importance of physical activity must be widely promoted through curricula and public health campaigns.

#### Family-Centered Preventive Approaches

Since hyperlipidemia often has a familial component, interventions should not be limited to the individual but include family-wide lifestyle counseling. Encouraging healthy behaviors within households can lead to more sustainable outcomes and reduce generational risk transmission.

#### Further Research on Pathophysiology and Genetic Markers

More studies are needed to explore the molecular and genetic underpinnings of adolescent dyslipidemia. Identification of novel biomarkers and genetic variants associated with lipid abnormalities could enhance early detection and allow for precision medicine approaches in the future.

#### Longitudinal Studies on Outcomes

Large-scale, long-term studies tracking adolescents with hyperlipidemia into adulthood are essential to fully understand the natural history of the disease and the effectiveness of early interventions. Such studies will inform policy development and clinical practice guidelines over time.

Access to Affordable Diagnostics and Treatment

In many low-resource settings, adolescents lack access to affordable lipid testing and appropriate therapeutic options. Governments and healthcare institutions must work toward making diagnostic tools and medications, such as statins (if indicated), accessible and affordable for younger populations.

Use of Digital Health Tools and Mobile Apps

Digital platforms and mobile health applications can play a significant role in health education, self-monitoring of dietary habits, and encouraging physical activity among tech-savvy adolescents. Future interventions should explore the integration of such tools into broader public health strategies.

**7. References**

- arter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., ... & Waters, D. D. (2007). HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. *New England Journal of Medicine*, 357(13), 1301–1310. <https://doi.org/10.1056/NEJMoa064278>
- Berenson, G. S., Srinivasan, S. R., Bao, W., Newman, W. P., Tracy, R. E., & Wattigney, W. A. (1998). Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. *New England Journal of Medicine*, 338(23), 1650–1656. <https://doi.org/10.1056/NEJM199806043382302>
- Braamskamp, M. J. A. M., Wijburg, F. A., & Wiegman, A. (2012). Drug treatment of hypercholesterolemia in children and adolescents. *Drugs*, 72(6), 759–772. <https://doi.org/10.2165/11631970-000000000-00000>
- Centers for Disease Control and Prevention. (2022). Childhood obesity facts. <https://www.cdc.gov/obesity/data/childhood.html>
- Daniels, S. R., & Greer, F. R. (2008). Lipid screening and cardiovascular health in childhood. *Pediatrics*, 122(1), 198–208. <https://doi.org/10.1542/peds.2008-1349>
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. (2011). Summary report. *Pediatrics*, 128(Suppl 5), S213–S256. <https://doi.org/10.1542/peds.2009-2107C>
- Goldberg, I. J. (2001). Clinical review 124: Diabetic dyslipidemia: Causes and consequences. *Journal of Clinical Endocrinology & Metabolism*, 86(3), 965–971. <https://doi.org/10.1210/jcem.86.3.7323>
- Jolliffe, C. J., & Janssen, I. (2006). Distribution of lipoproteins by age and sex in adolescents. *Circulation*, 114(10), 1056–1062. <https://doi.org/10.1161/CIRCULATIONAHA.106.620864>
- Kwiterovich, P. O. (2000). The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: A current review. *American Journal of Cardiology*, 86(12A), 5L–10L. [https://doi.org/10.1016/S0002-9149\(00\)01337-0](https://doi.org/10.1016/S0002-9149(00)01337-0)
- Libby, P. (2002). Inflammation in atherosclerosis. *Nature*, 420(6917), 868–874. <https://doi.org/10.1038/nature01323>

- McGill, H. C., McMahan, C. A., & Gidding, S. S. (2000). Preventing heart disease in the 21st century: Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. *Circulation*, 100(11), 1103–1113. <https://doi.org/10.1161/01.CIR.100.11.1103>
- Raj, M., Kumar, R. K., & Sundaram, K. R. (2020). Obesity and dyslipidemia among adolescents. *Indian Journal of Pediatrics*, 87\*(2), 123–130. [https://www.researchgate.net/publication/283072474\\_Hyperlipidemia\\_Etiology\\_and\\_Possible\\_Control](https://www.researchgate.net/publication/283072474_Hyperlipidemia_Etiology_and_Possible_Control)
- <https://www.ncbi.nlm.nih.gov/books/NBK559182/>
- Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. *Ann Intern Med*. 1971 Sep;75(3):471-2.
- Ballantyne CM, Grundy SM, Oberman A, Kreisberg RA, Havel RJ, Frost PH, Haffner SM. Hyperlipidemia: diagnostic and therapeutic perspectives. *J Clin Endocrinol Metab*. 2000 Jun;85(6):2089-112.
- Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J., American Heart Association. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. *Circulation*. 2004 Jun 01;109(21):2617-25.
- Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. *Am J Cardiol*. 2012 Sep 15;110(6):823-5.
- Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA*. 1986 Nov 28;256(20):2823-8. [PubMed]
- The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA*. 1984 Jan 20;251(3):365-74.
- Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT., ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*. 2016 Oct 14;37(39):2999-3058.
- Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA., GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. *JAMA*. 2016 Apr 19;315(15):1580-90.
- Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of

- Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. *Circulation*. 2017 Nov 14;136(20):1878-1891. [PubMed]
- Ford I, Murray H, McCowan C, Packard CJ. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. *Circulation*. 2016 Mar 15;133(11):1073-80. [PMC free article] [PubMed]
- Franklin BA, Brubaker P, Harber MP, Lavie CJ, Myers J, Kaminsky LA. The Journal of Cardiopulmonary Rehabilitation and Prevention at 40 yr and Its Role in Promoting Preventive Cardiology: Part 2. *J Cardiopulm Rehabil Prev*. 2020 Jul;40(4):209-214. [PubMed]
- Álvarez C, Ramírez-Campillo R, Lucia A, Ramírez-Vélez R, Izquierdo M. Concurrent exercise training on hyperglycemia and comorbidities associated: Non-responders using clinical cutoff points. *Scand J Med Sci Sports*. 2019 Jul;29(7):952-967. [PubMed]
- Bakker EA, Lee DC, Sui X, Eijsvogels TMH, Ortega FB, Lee IM, Lavie CJ, Blair SN. Association of Resistance Exercise With the Incidence of Hypercholesterolemia in Men. *Mayo Clin Proc*. 2018 Apr;93(4):419-428. [PMC free article] [PubMed]